Nathaniel Alzofon

Nathaniel Alzofon

Auto-generated profile, based on publicly available information

Nathaniel Alzofon

Division of Medical Oncology, Department of Medicine, University of Colorado Denver School of Medicine (UCDSOM), Aurora, Colorado

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2025 in Cancer Research Communications
Verified
Journal Article
Open access
JMJ. Jason Morton
J. Jason Morton
SRStephan A. Ramos
Stephan A. Ramos
NANathaniel Alzofon
Nathaniel Alzofon
SKStephen B. Keysar
Stephen B. Keysar
LALucas H. Armitage
Lucas H. Armitage
AJAntonio Jimeno
Antonio Jimeno
A fundamental limitation of HLA-A matched humanized mice (mHM), generated with donor hematopoietic stem and progenitor cells and bearing patient-derived xenografts, is that the fidelity of the interaction between the immune system and implanted tumors is limited by lack of thymic T-cell education. We created a model with patient-matched thymic and tumor tissue by using patient peripheral blood mononuclear cells reprogrammed into induced pluripotent stem cells to generate stem cell–derived thymic organoids (sTOs). When implanted in thymectomized mHM, which were subsequently engrafted with patient melanoma tissue (autologous, or mHMTA), sTOs expressed thymic tissue markers EPCAM, KRT5, and KRT8 and contained developing double-positive T cells. mHMTA had more activated HLA-DR+ T cells in their spleens. Tumor growth in mHMTA was significantly slower compared with mHM, and both tumor volume and viable melanoma content were significantly decreased in mHMTA. This was associated with an increase of intratumoral activated T cells in mHMTA. Whole-exome sequencing followed by intratumoral heterogeneity analysis identified seven candidate neoantigens that were selected against in the mHMTA model, suggesting more effective identification and T cell–driven tumor clearance. This study shows the feasibility of generating patient-specific, thymus-bearing mice and provides a promising new tool in immunology and immunotherapy development. Significance: A humanized mouse xenograft model, in which T cells are educated in a patient-derived implanted thymic organoid autologous to the tumor, provides a more faithful and complete environment to study cancer immunity.

24 November 2025
Verified
Other
Open access
JMJ. Jason Morton
J. Jason Morton
SRStephan A. Ramos
Stephan A. Ramos
NANathaniel Alzofon
Nathaniel Alzofon
SKStephen B. Keysar
Stephen B. Keysar
LALucas H. Armitage
Lucas H. Armitage
AJAntonio Jimeno
Antonio Jimeno
A fundamental limitation of HLA-A matched humanized mice (mHM), generated with donor hematopoietic stem and progenitor cells and bearing patient-derived xenografts, is that the fidelity of the interaction between the immune system and implanted tumors is limited by lack of thymic T-cell education. We created a model with patient-matched thymic and tumor tissue by using patient peripheral blood mononuclear cells reprogrammed into induced pluripotent stem cells to generate stem cell–derived thymic organoids (sTOs). When implanted in thymectomized mHM, which were subsequently engrafted with patient melanoma tissue (autologous, or mHMTA), sTOs expressed thymic tissue markers EPCAM, KRT5, and KRT8 and contained developing double-positive T cells. mHMTA had more activated HLA-DR+ T cells in their spleens. Tumor growth in mHMTA was significantly slower compared with mHM, and both tumor volume and viable melanoma content were significantly decreased in mHMTA. This was associated with an increase of intratumoral activated T cells in mHMTA. Whole-exome sequencing followed by intratumoral heterogeneity analysis identified seven candidate neoantigens that were selected against in the mHMTA model, suggesting more effective identification and T cell–driven tumor clearance. This study shows the feasibility of generating patient-specific, thymus-bearing mice and provides a promising new tool in immunology and immunotherapy development.Significance:A humanized mouse xenograft model, in which T cells are educated in a patient-derived implanted thymic organoid autologous to the tumor, provides a more faithful and complete environment to study cancer immunity.


24 November 2025
Verified
Other
Open access
JMJ. Jason Morton
J. Jason Morton
SRStephan A. Ramos
Stephan A. Ramos
NANathaniel Alzofon
Nathaniel Alzofon
SKStephen B. Keysar
Stephen B. Keysar
LALucas H. Armitage
Lucas H. Armitage
AJAntonio Jimeno
Antonio Jimeno
Changes in intratumoral heterogeneity in mHMTA PDXs can be explained by neoAg selection. A, NeoAg distribution across HLA alleles (B) Kullback–Leibler logos show enrichment of hydrophobic amino acids at position 9 in the neoAg pool. The height of each one letter amino acid code is the absolute enrichment relative to unselected peptides. Values above the x axis are positively enriched whereas those below are depleted. C, Distribution of estimated changes in variant allele frequency between the mHMTA and mHM models in all variants identified by exome sequencing. Values to the right of the dotted line represent variants that enriched, or underwent positive selection in mHMTA, whereas values to the left represent variants that underwent negative selection. D, Significant changes between mHM and mHMTA variant allele frequencies are plotted against the predicted HLA binding affinity for nine-mer peptides derived from each variant. The points are colored by which class I HLA molecule the peptide was predicted to bind. All significantly altered variants were found to produce at least two neoAgs. Error bars represent SE. E, Single letter codes for each amino acid are shown with the mutant residue outlined in each. The majority of mutations occurred at TCR contact residue locations (positions 3–8).

24 November 2025
Verified
Other
Open access
JMJ. Jason Morton
J. Jason Morton
SRStephan A. Ramos
Stephan A. Ramos
NANathaniel Alzofon
Nathaniel Alzofon
SKStephen B. Keysar
Stephen B. Keysar
LALucas H. Armitage
Lucas H. Armitage
AJAntonio Jimeno
Antonio Jimeno
In vitro patient-specific sTO characterization. A, Differentiation of patient-derived iPSCs to TEPs and subsequent production of sTOs. iPSCs are differentiated into TEPs. Coculture of allogeneic (for in vitro examination of the sTOs) or HLA-A–matched HSPCs (for in vivo experiments) at the air–liquid interface produces sTOs with functional TECs. B, qPCR examination of key thymic marker expression in sTOs in vitro. The fold change (2−ddCt) in the expression of these genes in sTO cultures at 0-, 3-, and 6-week timepoints was compared with that of undifferentiated iPSCs. Significance was determined using a one-way ANOVA with a Tukey multiple comparison test. cTEC, cortical TEC; mTEC, medullary TEC. C, qPCR examination of tissue-restricted antigen expression in vitro, indicative of AIRE activity, calculated and with significance as determined above. D, IF microscopy of sTOs after 3 weeks of culture shows cell structures expressing thymic markers and identifies presumptive T cells within these structures. DP T cells are indicated by white arrows. Magnification is 40×. Scale bar, 100 μm. E, Cytometry of dissociated sTOs to identify maturing T cells. CD5/7 proT cells were identified after gating CD45+ cells, whereas CD4/8+ T cells were identified after gating CD45 and CD3/TCRαβ cells. P values: *, ≤0.05; **, ≤0.01; *** ≤0.001.